| 1560 |
National Cancer Institute |
Html |
en |
Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of bile duct cancer. |
| cancer treatment | 0.353124 |
| bile ducts | 0.564994 |
| bile duct cancer | 0.93969 |
| body | 0.371618 |
| Recurrent bile duct | 0.466297 |
| extrahepatic bile duct | 0.483916 |
| PDQ cancer information | 0.368 |
| resectable perihilar bile | 0.374861 |
| perihilar bile duct | 0.569945 |
| clinical trial search | 0.384576 |
| bile duct | 0.961515 |
| clinical trials | 0.565197 |
| nearby lymph nodes | 0.369687 |
| cancer information summary | 0.357079 |
| resectable bile duct | 0.431592 |
| bile duct cancers | 0.440742 |
| liver | 0.42559 |
| patients | 0.355382 |
| clinical trial | 0.45121 |
| distal extrahepatic bile | 0.464256 |
| radiation therapy | 0.471059 |
| small intestine | 0.398038 |
| intrahepatic bile duct | 0.502288 |
| treatment | 0.464058 |
| transhepatic biliary drainage | 0.355933 |
|
| NCI-supported cancer | 0.356212 |
| cancer cells | 0.412313 |
| bile duct wall | 0.415716 |
| stage bile duct | 0.454009 |
| metastatic perihilar bile | 0.377513 |
| common bile duct | 0.446017 |
| National Cancer Institute | 0.386156 |
| Stent placement | 0.359539 |
| metastatic bile duct | 0.439918 |
| new treatment | 0.359129 |
| common hepatic duct | 0.40199 |
| external radiation therapy | 0.3932 |
| carry bile | 0.373127 |
| procedure | 0.357714 |
| swollen bile ducts | 0.401928 |
| cystic duct | 0.364061 |
| cancer clinical trials | 0.390707 |
| duct cancer cells | 0.3797 |
| resectable intrahepatic bile | 0.377924 |
| tumor | 0.353722 |
| intrahepatic bile ducts | 0.394408 |
| internal radiation therapy | 0.382915 |
| metastatic intrahepatic bile | 0.380622 |
| information | 0.370053 |
|
CLICK HERE |
| 1576 |
National Cancer Institute |
Html |
en |
Prostate Cancer Screening (PDQ®)–Patient Version |
Expert-reviewed information summary about tests used to detect or screen for prostate cancer. |
| PDQ Screening | 0.238955 |
| prostate gland | 0.262783 |
| following PDQ summaries | 0.255959 |
| Cancer Information Service | 0.234967 |
| PDQ cancer information | 0.447798 |
| Prevention Editorial Board | 0.248763 |
| men | 0.210517 |
| National Cancer Institute | 0.335949 |
| clinical trials | 0.389256 |
| PDQ documents | 0.200757 |
| test result | 0.223183 |
| benign prostatic hyperplasia | 0.273839 |
| cancer information summary | 0.326548 |
| newly diagnosed prostate | 0.284247 |
| clinical trial | 0.213023 |
| new treatment | 0.208327 |
| breast cancer prevention | 0.217981 |
| early cancer detection | 0.236129 |
|
| Cancer screening trials | 0.28054 |
| test | 0.242059 |
| Cancer Care page | 0.221557 |
| PDQ database | 0.205174 |
| prostate cancer gene | 0.339499 |
| NCI’s PDQ | 0.209119 |
| prostate cancer screening | 0.411947 |
| PDQ summary | 0.286479 |
| cancer symptoms | 0.211597 |
| NCI PDQ cancer | 0.287762 |
| prostate cancer | 0.971006 |
| tests | 0.264624 |
| bigger prostate | 0.262229 |
| PSA test | 0.20487 |
| Prostate Cancer Prevention | 0.350483 |
| cancer information summaries | 0.242796 |
| comprehensive cancer information | 0.243032 |
| high PSA level | 0.200418 |
|
CLICK HERE |
| 1580 |
National Cancer Institute |
Html |
en |
Skin Cancer Screening (PDQ®)–Patient Version |
Having a skin exam to screen for skin cancer has not been shown to decrease your chance of dying from skin cancer. Learn about this and other tests that have been studied to detect or screen for skin cancer in this expert reviewed summary. |
| PDQ Screening | 0.323371 |
| skin cancer | 0.833312 |
| cancer treatment | 0.285886 |
| cancer screening methods | 0.360926 |
| United States | 0.282138 |
| ongoing clinical trials | 0.355632 |
| screening tests | 0.287638 |
| cancer cells | 0.293854 |
| following PDQ summaries | 0.338661 |
| Cancer Information Service | 0.328048 |
| PDQ cancer information | 0.497713 |
| squamous cells | 0.320712 |
| squamous cell skin | 0.32842 |
| white men | 0.281879 |
| Prevention Editorial Board | 0.34433 |
| treatment clinical trials | 0.288708 |
| National Cancer Institute | 0.431189 |
| clinical trials | 0.547197 |
| PDQ documents | 0.289835 |
| inner layer | 0.288892 |
| test result | 0.316842 |
| cancer information summary | 0.417477 |
| melanoma skin cancer | 0.385616 |
| new treatment | 0.294602 |
|
| breast cancer prevention | 0.311531 |
| skin cancer screening | 0.419518 |
| Cancer screening trials | 0.367401 |
| NCI website | 0.290521 |
| Regular skin checks | 0.306952 |
| Cancer Care page | 0.315809 |
| PDQ database | 0.293213 |
| latest published information | 0.29227 |
| risk factor | 0.309102 |
| NCI’s PDQ | 0.299274 |
| PDQ summary | 0.314752 |
| UV radiation | 0.308073 |
| cancer symptoms | 0.303698 |
| doctor | 0.289249 |
| NCI PDQ cancer | 0.373425 |
| tests | 0.320045 |
| cancer information summaries | 0.334989 |
| nonmelanoma skin cancer | 0.420432 |
| comprehensive cancer information | 0.335151 |
| basal cell carcinoma | 0.354359 |
| cancer | 0.95489 |
| basal cells | 0.2875 |
| squamous cell carcinoma | 0.357881 |
|
CLICK HERE |
| 1631 |
National Cancer Institute |
Html |
en |
Merkel Cell Carcinoma Treatment (PDQ®)–Patient Version |
Merkel cell carcinoma is a rare disease in which cancer cells form in Merkel cells in the skin and starts most often in areas of skin exposed to the sun. Find out about risk factors, symptoms, tests to diagnose, prognosis, staging, and treatment for Merkel cell carcinoma. |
| cancer treatment | 0.369679 |
| distant parts | 0.362908 |
| lymph node dissection | 0.588951 |
| body | 0.395316 |
| PDQ cancer information | 0.408963 |
| clinical trial search | 0.383573 |
| metastatic Merkel cell | 0.359176 |
| clinical trials | 0.614596 |
| nearby lymph nodes | 0.400683 |
| cancer information summary | 0.387551 |
| clinical trial | 0.501642 |
| Merkel cells | 0.371884 |
| tumor area | 0.368378 |
| patients | 0.364556 |
| lymph node biopsy | 0.419179 |
| sentinel lymph node | 0.455835 |
| radical lymph node | 0.418343 |
| Recurrent Merkel cell | 0.378899 |
| malignant tumor cells | 0.373594 |
| NCI PDQ cancer | 0.361276 |
| Treatment Option Overview | 0.361132 |
| lymph nodes | 0.564493 |
| radiation therapy | 0.43011 |
| Treatment Editorial Board | 0.360626 |
| general cancer information | 0.354614 |
|
| treatment | 0.462922 |
| wide local excision | 0.414099 |
| swollen lymph nodes | 0.431138 |
| NCI-supported cancer | 0.355921 |
| cancer cells | 0.429285 |
| Cancer Information Service | 0.355025 |
| treatment clinical trials | 0.372695 |
| National Cancer Institute | 0.42114 |
| Cell Carcinoma Treatment | 0.359564 |
| regional lymph node | 0.418618 |
| lymph vessels | 0.377608 |
| new treatment | 0.401967 |
| merkel cell carcinoma | 0.969094 |
| primary tumor | 0.368519 |
| cancer clinical trials | 0.393874 |
| stage | 0.380167 |
| cell lung cancer | 0.358436 |
| tumor | 0.434689 |
| comprehensive cancer information | 0.354073 |
| cancer | 0.71533 |
| information | 0.409547 |
| lymph ducts | 0.372558 |
| standard treatment | 0.354595 |
| physical exam | 0.362972 |
|
CLICK HERE |
| 1766 |
National Cancer Institute |
Html |
en |
Accidents at Nuclear Power Plants and Cancer Risk |
A fact sheet about cancer risks associated with accidents at nuclear power plants. |
| Atomic Radiation | 0.316376 |
| Radiation risks | 0.325562 |
| radiation exposures | 0.328269 |
| nuclear accident sites | 0.293301 |
| Radiation Research | 0.323015 |
| low levels | 0.272065 |
| nuclear power plant | 0.97677 |
| I-131 exposure | 0.297263 |
| radiation sickness | 0.405841 |
| high doses | 0.352667 |
| radiation emergencies | 0.31438 |
| Chernobyl nuclear power | 0.302487 |
| Additional radioactive isotopes | 0.311741 |
| dangerous radioactive isotopes | 0.306851 |
| cancer patients | 0.299868 |
| greatest cancer risks | 0.294897 |
| cancer risks | 0.312758 |
| radioactive materials | 0.379547 |
| radiation therapy | 0.335122 |
| unstable isotopes | 0.274 |
| Radiation Effects Research | 0.350011 |
| external radiation | 0.312725 |
| power plant disaster | 0.278559 |
| radioactive isotopes | 0.53284 |
| ionizing radiation | 0.412892 |
|
| health effects | 0.355744 |
| future nuclear accidents | 0.300229 |
| nuclear reactors | 0.284713 |
| power plant accident | 0.397996 |
| nuclear weapons explosions | 0.282249 |
| thyroid gland | 0.292634 |
| thyroid cancer | 0.388789 |
| radiation exposure | 0.375545 |
| power plant accidents | 0.566854 |
| Radiation Emergency Medical | 0.344768 |
| I-131 | 0.306486 |
| radioactive exposure | 0.273465 |
| National Cancer Institute | 0.340697 |
| specific radioactive materials | 0.295979 |
| breast cancer risk | 0.282358 |
| Radiation Epidemiology Branch | 0.341242 |
| Chernobyl-related thyroid cancer | 0.291023 |
| radiation | 0.697647 |
| cancer risk | 0.309268 |
| et al | 0.275755 |
| medical x-ray machines | 0.33168 |
| cancer | 0.423405 |
| Chernobyl accident | 0.42803 |
| certain radioactive isotopes | 0.3079 |
|
CLICK HERE |
| 1863 |
National Cancer Institute |
Html |
es |
Tratamiento de la leucemia de células pilosas (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de la leucemia de células pilosas. |
| cell leukemia treated | 0.413444 |
| cell leukemia patients | 0.427269 |
| long-term follow-up | 0.427434 |
| Rituximab with pentostatin | 0.40359 |
| Peaud PY | 0.40245 |
| hairy cell leukaemia | 0.411122 |
| initially with pentostatin | 0.406363 |
| Foucar MK | 0.403895 |
| leukemia patients treated | 0.417121 |
| leukemia following treatment | 0.406508 |
| células pilosas | 0.473847 |
| treated with rituximab | 0.403745 |
| Instituto Nacional | 0.402568 |
| cell leukemia following | 0.408562 |
| Else M | 0.404329 |
| with pentostatin | 0.442439 |
| or refractory hairy | 0.403457 |
| VH4-34+ hairy cell | 0.404297 |
| Natl Cancer Inst | 0.402731 |
| Federico M | 0.402782 |
| Leuk Lymphoma | 0.424893 |
| long term | 0.40908 |
| patients treated with | 0.423309 |
| Burian C | 0.403658 |
| Matutes E | 0.403796 |
|
| leukemia treated with | 0.41301 |
| patients with hairy | 0.610395 |
| following treatment with | 0.408927 |
| Italian Cooperative Group | 0.40697 |
| hairy-cell leukemia with | 0.408245 |
| relapsed or refractory | 0.403586 |
| National Cancer Institute | 0.404377 |
| after treatment with | 0.408757 |
| untreated patients with | 0.407444 |
| with poor prognosis | 0.40323 |
| with 2-CdA | 0.403201 |
| cell leukemia with | 0.426877 |
| treatment with | 0.420376 |
| hairy cell leukemia | 0.998262 |
| Clin Oncol | 0.444146 |
| treated with pentostatin | 0.422653 |
| leukemia with pentostatin | 0.404444 |
| leukemia after treatment | 0.406381 |
| Long term results | 0.402405 |
| treated with | 0.429875 |
| treated initially with | 0.406289 |
| previously untreated patients | 0.40321 |
| PDQ Sofocos | 0.402915 |
| cell leukemia after | 0.412869 |
|
CLICK HERE |
| 1994 |
National Cancer Institute |
Html |
es |
Tratamiento del craneofaringioma infantil (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del craneofaringioma infantil |
| childhood-onset craniopharyngioma | 0.555421 |
| Winkfield KM | 0.461372 |
| Merchant TE | 0.538632 |
| Pediatric Patients with | 0.460492 |
| largo plazo | 0.456579 |
| brain tumors | 0.465364 |
| cystic craniopharyngiomas | 0.546839 |
| pediatric craniopharyngiomas with | 0.478389 |
| after childhood-onset craniopharyngioma | 0.509117 |
| calcificación quizás | 0.453393 |
| craneofaringioma infantil grupo | 0.448145 |
| past treatment modalities | 0.44452 |
| Instituto Nacional | 0.469284 |
| Proton beam therapy | 0.44785 |
| proton radiotherapy | 0.445521 |
| Radiat Oncol Biol | 0.691179 |
| Pediatric Brain Tumor | 0.463199 |
| Endocrinol Metab | 0.525086 |
| Gebhardt U | 0.460882 |
| central nervous system | 0.452583 |
| proton therapy | 0.48171 |
| tumor control | 0.4621 |
| Optimal treatment strategy | 0.445937 |
| radiation therapy | 0.847388 |
| Clin Endocrinol Metab | 0.477641 |
|
| following treatment | 0.481728 |
| subtotal quizás | 0.449448 |
| Neurosurg Focus | 0.603105 |
| Pediatric MATCH | 0.494065 |
| pediatric craniopharyngioma | 0.961568 |
| tumores quÃsticos recidivantes | 0.450542 |
| PDQ Descripción | 0.449293 |
| Pediatr Blood Cancer | 0.611837 |
| after radiation therapy | 0.60095 |
| With Craniopharyngioma That | 0.51489 |
| efectos tardÃos | 0.785518 |
| PDQ Efectos tardÃos | 0.471103 |
| tumor control with | 0.459757 |
| Neurosurgical treatment | 0.478026 |
| National Cancer Institute | 0.453747 |
| with proton radiotherapy | 0.445448 |
| tumor quizás | 0.486067 |
| PDQ Tratamiento | 0.463786 |
| treatment strategy | 0.478645 |
| long-term results | 0.483149 |
| Oncol Biol Phys | 0.703438 |
| Neurosurg Pediatr | 0.66815 |
| long-term gh therapy | 0.447185 |
| patients with craniopharyngioma | 0.738686 |
|
CLICK HERE |
| 2048 |
National Cancer Institute |
Html |
es |
Pruebas de Papanicolaou y del virus del papiloma humano (VPH) |
Hoja informativa que describe los exámenes selectivos de detección del cáncer de cérvix, los cuales incluyen la prueba de Papanicolaou y la prueba de los virus del papiloma humano. |
| Lancet Oncology | 0.30494 |
| alta probabilidad | 0.305241 |
| Clinical Pathology | 0.316699 |
| siguientes categorÃas | 0.313238 |
| undergoing concurrent testing | 0.307924 |
| American Society | 0.338185 |
| Schiffman M | 0.323335 |
| pruebas conjuntas | 0.308272 |
| Sociedad Estadounidense | 0.311719 |
| Task Force Recommendation | 0.307945 |
| Preventive Services Task | 0.350595 |
| Cervical Pathology | 0.322689 |
| low-grade squamous | 0.308742 |
| Roche Molecular Systems | 0.307924 |
| Estados Unidos | 0.346024 |
| cervical cancer | 0.362845 |
| Clinical Pathology screening | 0.309437 |
| cobas hpv test | 0.3092 |
| PubMed Abstract | 0.387591 |
| categorÃa cin-2 | 0.304985 |
| categorÃa cin-3 | 0.305133 |
| human papillomavirus | 0.356046 |
| Cancer Journal | 0.30689 |
| atypical squamous cells | 0.360558 |
| Sistema Bethesda | 0.324914 |
|
| PatologÃa Cervical | 0.309863 |
| lesiones asc-h | 0.305566 |
| categorÃas cin-2 | 0.305175 |
| United States Preventive | 0.309063 |
| cuidado médico | 0.306651 |
| lesiones asc-us | 0.30675 |
| Katki HA | 0.31204 |
| alto riesgo | 0.931083 |
| clinical practice | 0.304727 |
| Drug Administration | 0.304664 |
| cervical cytology | 0.30862 |
| Servicios Preventivos | 0.304816 |
| Wacholder S | 0.311753 |
| resultado asc-us | 0.312665 |
| papillomavirus testing | 0.305257 |
| HPV cotesting | 0.306351 |
| resultados benignos | 0.305213 |
| Services Task Force | 0.349973 |
| cervical intraepithelial neoplasia | 0.314986 |
| mejores resultados | 0.304652 |
| Cancer Institute | 0.314518 |
| graves anomalÃas | 0.316853 |
| infecciones pasajeras | 0.309673 |
| squamous cell carcinoma | 0.313148 |
|
CLICK HERE |
| 16828 |
National Cancer Institute |
Html |
en |
Computational Genomics Research |
NCI’s Center for Cancer Genomics uses computational cancer genomics to derive insight about cancer genes and pathways using big data. |
| big datasets | 0.542777 |
| genomic analysis | 0.686648 |
| CCG data | 0.58375 |
| HD video | 0.465732 |
| computational approaches | 0.476443 |
| independent submitters | 0.444997 |
| Computational research | 0.470859 |
| statistical models | 0.4439 |
| analysis tools | 0.443955 |
| single cell DNA | 0.563687 |
| shares data | 0.501975 |
| large genomic datasets | 0.997114 |
| cancer driver mutations | 0.615431 |
| file cabinets | 0.459486 |
| Genomic Data Commons | 0.977931 |
| clinical datasets | 0.540686 |
| RNA expression | 0.456571 |
| multiple genomic platforms | 0.828302 |
| NCI’s Center | 0.447369 |
| exceedingly complex relationships | 0.649797 |
| Computational genomics research | 0.692909 |
| multiple modes | 0.445152 |
| cancer diagnostics | 0.487849 |
| oncogenic pathways | 0.463218 |
| computational techniques | 0.452264 |
|
| Genomics Data Analysis | 0.678168 |
| best ways | 0.449068 |
| cancer genomic data | 0.909069 |
| DNA sequence | 0.445849 |
| expert programming | 0.466152 |
| stores diverse datasets | 0.638138 |
| complex datasets | 0.550815 |
| cancer mechanisms | 0.478773 |
| scalable cloud environment | 0.595936 |
| unified view | 0.44922 |
| Genome Characterization Pipeline | 0.557584 |
| cancer researchers | 0.495463 |
| RNA sequencing | 0.45187 |
| democratize access | 0.474498 |
| Cancer Genomics Cloud | 0.816717 |
| Cancer Genome Atlas | 0.615653 |
| cancer genomic databases | 0.9082 |
| Genomics Cloud Pilots | 0.822542 |
| robust genomic data | 0.825715 |
| chromosomal copy number | 0.585632 |
| NCI Genomic Data | 0.844471 |
| exceedingly large number | 0.6264 |
| new technologies | 0.445699 |
| computationally-intensive genomic analyses | 0.756967 |
|
CLICK HERE |
| 17171 |
National Cancer Institute |
Html |
es |
PC-SPES (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos sobre el uso de PC-SPES como tratamiento del cáncer de próstata. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta. |
| médico herborista | 0.418438 |
| Centro Nacional | 0.430037 |
| New Hampshire Avenue | 0.420405 |
| Drug Administration | 0.412734 |
| NCI Best Case | 0.437012 |
| datos bibliográficos pubmed | 0.422243 |
| siguientes preguntas | 0.413766 |
| demostró efectos | 0.424258 |
| siguientes riesgos | 0.417668 |
| seguro médico | 0.412292 |
| múltiples problemas | 0.418438 |
| Instituto Nacional | 0.517971 |
| acupuntura ayuda | 0.412243 |
| Salud Complementaria | 0.450225 |
| Visuals Online | 0.415643 |
|
| complementarias revisa | 0.422417 |
| Physician Data Query | 0.491682 |
| Estados Unidos | 0.863449 |
| actúa pc-spes | 0.442835 |
| libre uso | 0.415953 |
| suficiente cantidad | 0.41905 |
| página manejo | 0.414584 |
| ¿El tratamiento | 0.421322 |
| Nueva York | 0.418373 |
| ¿Los beneficios | 0.413162 |
| siguientes medicamentos | 0.438285 |
| Series Program | 0.413051 |
| medicina complementaria | 0.925538 |
| diferentes lotes | 0.423892 |
|
CLICK HERE |